Nucleus Genomics on May 27, 2026 announced a landmark partnership with the Southern California Reproductive Center (SCRC), bringing its advanced Genetic Optimization technology to one of the most sought-after and respected fertility clinics in the United States. The announcement marks another major milestone in Nucleus' rapid global expansion, as the company's IVF+ Network now spans more than 160 clinics across India, the Middle East, and nearly all 50 U.S. states.

For SCRC patients, the partnership means direct access to two of Nucleus' flagship genomic services expanded carrier screening through its Preview product and advanced embryo analysis through its Embryo platform embedded as standard offerings within their IVF care experience.

A Partnership Built on Decades of Clinical Excellence

SCRC is not a newcomer to reproductive medicine. Co-founded and led by Dr. Mark Surrey and Dr. Hal C. Danzer, the center has spent more than 25 years helping individuals and couples build families through advanced reproductive technologies, including IVF, egg freezing, and genetic testing. In that time, its team has helped bring thousands of babies into the world, establishing SCRC as a trusted destination for fertility care not just in California but across the country.

The center operates across four California locations, Beverly Hills, Santa Barbara, Pasadena, and Ventura, and serves thousands of patients every year. That scale makes the integration of Nucleus' genomic capabilities particularly significant: advanced genetic analysis, once available only to a narrow subset of patients, will now be accessible to all patients undergoing IVF at SCRC. As Nucleus IVF+ joins SCRC's clinical framework, the move signals a broader shift in how leading fertility centres are approaching embryo selection and family planning, less as a one-size-fits-all medical process and increasingly as a precision-driven, genetically informed one.

What Patients Will Now Have Access To

Through the partnership, SCRC patients can opt into a substantially more comprehensive suite of genetic screening than has traditionally been available at most fertility clinics. Nucleus' technology provides insight into more than 2,000 rare inherited conditions, spanning the full spectrum from well-known conditions like cystic fibrosis and PKU to complex hereditary cancer syndromes that carry implications for both the child and the parent – including hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome. The platform also covers common conditions with significant long-term health consequences, including heart disease and diabetes, giving prospective parents a more complete picture of their embryos' genetic profiles before making decisions about selection.

Dr. Mark Surrey, co-founder of Southern California Reproductive Center, spoke directly to the clinical value: "Our ability to provide genetic screening for our patients' embryos gives patients access to testing that can offer reassurance. This remarkable breakthrough addresses concerns about birth defects, provides genetic analysis, and helps us assess an embryo's potential to result in a healthy pregnancy."

The ambition behind the partnership extends beyond individual patient outcomes. By making comprehensive genomic insight a standard part of the IVF process rather than an add-on, SCRC and Nucleus are positioning themselves at the forefront of what is being called preventive reproductive medicine, an approach that uses genetic analysis at the very start of life to reduce inherited risk across generations.

Nucleus' Expanding Global Footprint

For Nucleus Genomics, the SCRC announcement is the latest in a series of accelerating moves. Earlier this year, the company announced a partnership with Neway Fertility in New York and earlier still completed a sweeping rollout across 160+ clinics in India and the Middle East , one of the most ambitious geographic expansions in the company's history. Its IVF+ Network, the formal framework through which Nucleus integrates its technology into clinic partners, now reaches patients across virtually the entire United States and in multiple international markets.

The pace of that expansion reflects something the company says it is seeing consistently: patient and clinician demand for advanced genetic analysis in IVF is not a niche preference, it is becoming mainstream. Recent studies support that reading. According to research published in JAMA Network Open, nearly three-quarters of U.S. adults support the use of advanced genetic technologies during IVF. Newer survey data published in Reproductive Medicine in 2025 showed continued positive sentiment for polygenic embryo risk scores among the general public.

That demand is translating directly into scale. Nucleus currently has a waitlist of more than 3,000 patients, a figure that illustrates the gap between what prospective parents want and what has historically been available to them.

The Vision Behind the Network

Kian Sadeghi, founder and CEO of Nucleus Genomics, framed the clinical and human stakes of the partnership: "Patients want more insights on their embryos during IVF. Every patient has a loved one who suffered from a preventable condition, whether cancer, diabetes, or heart disease. SCRC, with their decades-long experience, is bringing preventive medicine to the start of life, helping patients understand their embryo's DNA to reduce genetic risk in the next generation."

That philosophy, that genomic insight at the point of IVF can meaningfully reduce the burden of inherited disease across future generations, is the foundation of Nucleus' IVF+ Network model. Rather than offering genetic analysis as a separate, optional service that patients must independently seek out and arrange, the IVF+ Network integrates it proactively into care. When Nucleus IVF+ joins SCRC's care model in this way, expanded carrier screening and embryo analysis become part of what every patient experiences, rather than something only the most informed or resourced patients encounter.